Pfizer’s (PFE) “Buy” Rating Reiterated at UBS AG

UBS AG reissued their buy rating on shares of Pfizer, Inc. (NYSE:PFE) in a research report report published on Monday, July 31st, www.flashratings.com reports. They currently have a $38.00 price target on the biopharmaceutical company’s stock.

PFE has been the subject of a number of other reports. Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the company a buy rating in a report on Monday, July 17th. BidaskClub upgraded shares of Pfizer from a strong sell rating to a sell rating in a report on Friday, June 23rd. Jefferies Group LLC reiterated a neutral rating and set a $35.00 price objective (up from $34.00) on shares of Pfizer in a report on Thursday, April 13th. Morgan Stanley reiterated a neutral rating and set a $38.00 price objective on shares of Pfizer in a report on Thursday, April 6th. Finally, Barclays PLC restated a buy rating and set a $38.00 price target on shares of Pfizer in a report on Wednesday, May 3rd. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $37.61.

Pfizer (PFE) traded down 0.85% on Monday, hitting $32.67. 15,490,145 shares of the stock were exchanged. The company has a market capitalization of $194.30 billion, a PE ratio of 23.90 and a beta of 1.00. The company has a 50-day moving average price of $33.30 and a 200 day moving average price of $33.38. Pfizer has a 1-year low of $29.83 and a 1-year high of $35.38.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the previous year, the firm posted $0.64 earnings per share. The business’s revenue was down 1.9% compared to the same quarter last year. Analysts anticipate that Pfizer will post $2.56 EPS for the current fiscal year.

WARNING: This story was first reported by Rincon Hill News and is the sole property of of Rincon Hill News. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://rinconhillneighbors.org/2017/08/19/pfizer-inc-pfe-given-buy-rating-at-ubs-ag-updated-updated.html.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.92%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.

In related news, CEO Ian C. Read sold 96,950 shares of the stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the transaction, the insider now owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in Pfizer by 2.3% in the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after buying an additional 9,239,499 shares during the last quarter. Norges Bank purchased a new stake in Pfizer during the fourth quarter worth approximately $1,896,890,000. Franklin Resources Inc. boosted its stake in Pfizer by 0.9% in the second quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock worth $1,550,754,000 after buying an additional 389,629 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Pfizer by 4.8% in the second quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock worth $1,487,617,000 after buying an additional 2,028,313 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its stake in Pfizer by 3.9% in the second quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock worth $1,143,248,000 after buying an additional 1,275,832 shares during the last quarter. 69.94% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.